Ac-Pro-Ala-Leu-AMC [Ac-PAL-AMC]
| Code | Size | Price |
|---|
| SBB-PS0007-M002 | 2 mg | £193.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Target Species: Human
Shipping:
Blue Ice
Storage:
4C
Documents
Further Information
Alternate Names/Synonyms:
Proteasome Substrate
Appearance:
Lyophilized powder.
CAS:
1431362-79-6
EClass:
32160000
Form (Short):
solid
Handling Advice:
Avoid freeze/thaw cycles.Protect from light.
InChi:
InChI=1S/C26H34N4O6/c1-14(2)11-20(25(34)28-18-8-9-19-15(3)12-23(32)36-22(19)13-18)29-24(33)16(4)27-26(35)21-7-6-10-30(21)17(5)31/h8-9,12-14,16,20-21H,6-7,10-11H2,1-5H3,(H,27,35)(H,28,34)(H,29,33)/t16-,20-,21-/m0/s1
InChiKey:
BWJPVHDZSJFFDM-NDXORKPFSA-N
Long Description:
Chemical. CAS: 1431362-79-6. Formula: C26H34N4O6. MW: 498.6. Synthetic. Ac-PAL-AMC is a fluorogenic peptide substrate for measuring caspase-like activity of the immunoproteasome. Hydrolysis of this substrate by the beta1i-subunit of the immunoproteasome is monitored by observing fluorescence at an Excitation wavelength of 345nm and Emission at 445nm. This substrate is specific to the immunoproteasome and is not hydrolyzed efficiently by the constitutive proteasome.
Molecular Formula:
C26H34N4O6
Molecular Weight:
498.6
Package Type:
Plastic Vial
Product Description:
Ac-PAL-AMC is a fluorogenic peptide substrate for measuring caspase-like activity of the immunoproteasome. Hydrolysis of this substrate by the beta1i-subunit of the immunoproteasome is monitored by observing fluorescence at an Excitation wavelength of 345nm and Emission at 445nm. This substrate is specific to the immunoproteasome and is not hydrolyzed efficiently by the constitutive proteasome.
Purity:
>95% (HPLC)
Sequence:
Acetyl-Pro-Ala-Leu-7-amido-4-methylcoumarin
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer: J.E. Park, et al.; PloS one 8, e73732 (2013) | Inhibitors of the immunoproteasome: current status and future directions: Z. Miller, et al.; Curr. Pharm. Des. 19, 4140 (2013) | Development and characterization of selective immunoproteasome inhibitors: C. Dubiella; Diss. Universitaet Muenchen (2015)